AmSpec Group, Inc., together with its subsidiaries (“AmSpec”), is a multinational group of companies within inspection, analysis and testing of products in the energy- and agricultural industries.

IIS Independent Inspection Services AB (“IIS”) conducts testing, inspection and a range of support services to the energy- and agricultural sectors in the Nordic market. The company has its main laboratory in Gothenburg.

The acquisition of IIS strengthens AmSpec’s position in the European market in general, and in the Nordic market in particular.

Vinge’s team mainly consisted of Jonas Johansson, Viktor Lennartsson, Robin Sultani (M&A), Karin Gynnerstedt (employment), Christoffer Nordin (commercial agreements), Karolina Fuhrman (IT and GDPR), Arvid Axelryd (IP), Markus Bernander (real estate), Ottilia Pettersson and Ellinore Boström Andersson (project assistants).

Related

Vinge has advised Morrow Bank AB (publ) in conjunction with the acquisition of MedMera Bank AB

Vinge has advised Morrow Bank AB (publ) in conjunction with the acquisition of all shares in MedMera Bank AB from Kooperativa Förbundet for a total consideration of SEK 1,960 million. The transaction positions Morrow Bank as a leading Nordic platform in consumer finance with combined gross loans of SEK 28.2 billion.
March 24, 2026

Vinge advises NEWS, a portfolio company of Litorina, in connection with the sale of Skandinavisk Kommunalteknik, FANN VA-Teknik and Alunda Polyeten to Wienerberger AG

Vinge advises Northern Environmental and Water Solutions AB (“NEWS”), a portfolio company of Litorina, in connection with the sale of the operating subsidiaries Skandinavisk Kommunalteknik, FANN VA-Teknik and Alunda Polyeten to Wienerberger AG (Vienna Stock Exchange: WIE). The transaction is expected to be completed in Q2 2026.
March 24, 2026

Vinge has advised Hansa Biopharma in connection with entering into a financing agreement

Vinge has advised Hansa Biopharma AB (publ), a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions, listed on Nasdaq Stockholm, in connection with a U.S. convertible note purchase agreement comprising USD 30 million aggregate principal amount of unsecured convertible senior notes.
March 23, 2026